Literature DB >> 35774715

A Case of Giant Cell Arteritis With a Normal Erythrocyte Sedimentation Rate (ESR) Post ChAdOx1 nCoV-19 Vaccination.

Chenfan Xia1, Rachel Edwards2, Bita Omidvar3.   

Abstract

Giant cell arteritis (GCA) has been reported post the coronavirus disease 2019 (COVID-19) vaccination, especially with the mRNA vaccine. A normal erythrocyte sedimentation rate (ESR) is seen in some GCA patients. This report describes a 68-year-old gentleman who presented with a right-sided temporal headache for three weeks, starting three to five days after his second dose of the ChAdOx1 nCoV-19 vaccine, a viral vector vaccine, which was given seven weeks post the first dose. On presentation, he developed blurred vision in the left eye, and it progressed to complete vision loss four days later. He also had episodes of blurred vision in the right eye. The blood test showed a mildly elevated C-reactive protein of 29 mg/L and a normal erythrocyte sedimentation rate (ESR) of 4 mm/hr. Optical coherence tomography showed anterior ischaemic optic neuropathy in the left eye and retinal ischemia in the right eye. Bilateral giant cell arteritis (GCA) was confirmed on temporal artery biopsy. He was treated with methylprednisolone pulse therapy followed by prednisolone. He re-presented with intermittent blurry vision in the right eye three months later. He was treated with methylprednisolone pulse therapy again, followed by prednisolone, aspirin, and tocilizumab. This case describes a patient who developed GCA post ChAdOx1 nCoV-19 vaccination with a normal ESR. Further studies are needed to investigate this relationship as causal or incidental and the likelihood of low-level inflammatory makers in such a situation.
Copyright © 2022, Xia et al.

Entities:  

Keywords:  covid; covid-19; covid-19 vaccine; covid-19 vaccine complication; esr; gca; inflammatory processes/inflammatory markers; normal esr; temporal artertitis

Year:  2022        PMID: 35774715      PMCID: PMC9236663          DOI: 10.7759/cureus.25388

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  16 in total

1.  Giant cell arteritis with an erythrocyte sedimentation rate lower than 50.

Authors:  V M Martínez-Taboada; R Blanco; J Armona; E Uriarte; M Figueroa; M A Gonzalez-Gay; V Rodriguez-Valverde
Journal:  Clin Rheumatol       Date:  2000       Impact factor: 2.980

2.  Infections and the risk of incident giant cell arteritis: a population-based, case-control study.

Authors:  Rennie L Rhee; Peter C Grayson; Peter A Merkel; Gunnar Tomasson
Journal:  Ann Rheum Dis       Date:  2016-11-28       Impact factor: 19.103

3.  Increased rather than decreased incidence of giant-cell arteritis during the COVID-19 pandemic.

Authors:  Augustin Lecler; Delphine Villeneuve; Catherine Vignal; Thomas Sené
Journal:  Ann Rheum Dis       Date:  2020-08-07       Impact factor: 19.103

4.  Case of Giant Cell Arteritis After SARS-CoV-2 Vaccination: A Particular Phenotype?

Authors:  Agathe Sauret; Julien Stievenart; Perrine Smets; Louis Olagne; Benedicte Guelon; Olivier Aumaître; Marc André; Ludovic Trefond
Journal:  J Rheumatol       Date:  2021-10-01       Impact factor: 5.346

5.  COVID-19 Recombinant mRNA Vaccines and Serious Ocular Inflammatory Side Effects: Real or Coincidence?

Authors:  Arash Maleki; Sydney Look-Why; Ambika Manhapra; C Stephen Foster
Journal:  J Ophthalmic Vis Res       Date:  2021-07-29

6.  Large-vessel giant cell arteritis after COVID-19 vaccine.

Authors:  A Mejren; C M Sørensen; L C Gormsen; R S Tougaard; B D Nielsen
Journal:  Scand J Rheumatol       Date:  2021-09-28       Impact factor: 3.641

7.  SARS-CoV-2 infection triggering a giant cell arteritis.

Authors:  Núria Riera-Martí; Jorge Romaní; Joan Calvet
Journal:  Med Clin (Engl Ed)       Date:  2021-03-11

8.  Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series.

Authors:  Leon D Kaulen; Sofia Doubrovinskaia; Christoph Mooshage; Berit Jordan; Jan Purrucker; Carmen Haubner; Corinna Seliger; Hanns-Martin Lorenz; Simon Nagel; Brigitte Wildemann; Martin Bendszus; Wolfgang Wick; Silvia Schönenberger
Journal:  Eur J Neurol       Date:  2021-10-31       Impact factor: 6.288

9.  New-onset giant cell arteritis following COVID-19 mRNA (BioNTech/Pfizer) vaccine: a double-edged sword?

Authors:  Ana M Anzola; Laura Trives; Julia Martínez-Barrio; Blanca Pinilla; José María Álvaro-Gracia; Juan Molina-Collada
Journal:  Clin Rheumatol       Date:  2022-02-03       Impact factor: 3.650

10.  Large-vessel vasculitis following the Pfizer-BioNTech COVID-19 vaccine.

Authors:  Michele Gilio; Giulio De Stefano
Journal:  Intern Emerg Med       Date:  2022-01-24       Impact factor: 5.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.